BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28134926)

  • 1. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma.
    Sheffield NC; Pierron G; Klughammer J; Datlinger P; Schönegger A; Schuster M; Hadler J; Surdez D; Guillemot D; Lapouble E; Freneaux P; Champigneulle J; Bouvier R; Walder D; Ambros IM; Hutter C; Sorz E; Amaral AT; de Álava E; Schallmoser K; Strunk D; Rinner B; Liegl-Atzwanger B; Huppertz B; Leithner A; de Pinieux G; Terrier P; Laurence V; Michon J; Ladenstein R; Holter W; Windhager R; Dirksen U; Ambros PF; Delattre O; Kovar H; Bock C; Tomazou EM
    Nat Med; 2017 Mar; 23(3):386-395. PubMed ID: 28134926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
    Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
    Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor.
    Roberto GM; Vieira GM; Delsin LEA; Silva MO; Hakime RG; Engel EE; Scrideli CA; Tone LG; Brassesco MS
    Cancer Genet; 2019 Jan; 230():21-27. PubMed ID: 30470587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.
    Katschnig AM; Kauer MO; Schwentner R; Tomazou EM; Mutz CN; Linder M; Sibilia M; Alonso J; Aryee DNT; Kovar H
    Oncogene; 2017 Oct; 36(43):5995-6005. PubMed ID: 28671673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.
    Yasir M; Park J; Chun W
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.
    Grünewald TG; Bernard V; Gilardi-Hebenstreit P; Raynal V; Surdez D; Aynaud MM; Mirabeau O; Cidre-Aranaz F; Tirode F; Zaidi S; Perot G; Jonker AH; Lucchesi C; Le Deley MC; Oberlin O; Marec-Bérard P; Véron AS; Reynaud S; Lapouble E; Boeva V; Rio Frio T; Alonso J; Bhatia S; Pierron G; Cancel-Tassin G; Cussenot O; Cox DG; Morton LM; Machiela MJ; Chanock SJ; Charnay P; Delattre O
    Nat Genet; 2015 Sep; 47(9):1073-8. PubMed ID: 26214589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
    Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
    J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
    Sankar S; Theisen ER; Bearss J; Mulvihill T; Hoffman LM; Sorna V; Beckerle MC; Sharma S; Lessnick SL
    Clin Cancer Res; 2014 Sep; 20(17):4584-97. PubMed ID: 24963049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma.
    Johnson KM; Taslim C; Saund RS; Lessnick SL
    PLoS One; 2017; 12(11):e0186275. PubMed ID: 29091716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1.
    Tomazou EM; Sheffield NC; Schmidl C; Schuster M; Schönegger A; Datlinger P; Kubicek S; Bock C; Kovar H
    Cell Rep; 2015 Feb; 10(7):1082-95. PubMed ID: 25704812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linking germline and somatic variation in Ewing sarcoma.
    Gomez NC; Davis IJ
    Nat Genet; 2015 Sep; 47(9):964-5. PubMed ID: 26313223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.
    Tilan JU; Krailo M; Barkauskas DA; Galli S; Mtaweh H; Long J; Wang H; Hawkins K; Lu C; Jeha D; Izycka-Swieszewska E; Lawlor ER; Toretsky JA; Kitlinska JB
    Cancer; 2015 Mar; 121(5):697-707. PubMed ID: 25387699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma.
    Adane B; Alexe G; Seong BKA; Lu D; Hwang EE; Hnisz D; Lareau CA; Ross L; Lin S; Dela Cruz FS; Richardson M; Weintraub AS; Wang S; Iniguez AB; Dharia NV; Conway AS; Robichaud AL; Tanenbaum B; Krill-Burger JM; Vazquez F; Schenone M; Berman JN; Kung AL; Carr SA; Aryee MJ; Young RA; Crompton BD; Stegmaier K
    Cancer Cell; 2021 Jun; 39(6):827-844.e10. PubMed ID: 34129824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1.
    Lin L; Huang M; Shi X; Mayakonda A; Hu K; Jiang YY; Guo X; Chen L; Pang B; Doan N; Said JW; Xie J; Gery S; Cheng X; Lin Z; Li J; Berman BP; Yin D; Lin DC; Koeffler HP
    Nucleic Acids Res; 2019 Feb; 47(3):1255-1267. PubMed ID: 30496486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
    Marques Howarth M; Simpson D; Ngok SP; Nieves B; Chen R; Siprashvili Z; Vaka D; Breese MR; Crompton BD; Alexe G; Hawkins DS; Jacobson D; Brunner AL; West R; Mora J; Stegmaier K; Khavari P; Sweet-Cordero EA
    J Clin Invest; 2014 Dec; 124(12):5275-90. PubMed ID: 25401475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
    Yuan B; Ji W; Xia H; Li J
    Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical heterogeneity of round cell sarcomas with EWSR1/FUS gene fusions: Impact of gene fusion type on clinical features and outcome.
    Tsuda Y; Zhang L; Meyers P; Tap WD; Healey JH; Antonescu CR
    Genes Chromosomes Cancer; 2020 Sep; 59(9):525-534. PubMed ID: 32362012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.